Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 1-2/2008

01.10.2008

HSP60 and Anti-HSP60 Antibodies in Vasculitis: They are Two of a Kind

verfasst von: Jean-Eric Alard, Maryvonne Dueymes, Pierre Youinou, Christophe Jamin

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1-2/2008

Einloggen, um Zugang zu erhalten

Abstract

Clinical and pathological manifestations present as heterogeneous in vasculitides. Thus, inflammation can affect arteries, arterioles, capillaries, venules, and veins toward major body regions. One common feature of vascular diseases appears to be the presence of anti-HSP60 autoantibodies arising either consecutively to infection and molecular mimicry reaction with bacterial HSP60, or following recognition of endogenous HSP60 translocated or bound onto the surface of stressed endothelial cells. Because their levels are very low in some diseases but strikingly upregulated in others, and because their frequencies vary from one vasculitis to another, anti-HSP60 autoantibodies might play a role in the pathological mechanisms that likely differ among the vascular diseases. Identification of the variety of HSP60 epitope specificities along with each vasculitis would help to understand such discrepancies.
Literatur
1.
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedCrossRef
2.
Savage CO, Harper L, Cockwell P, Adu D, Howie AJ (2000) ABC of arterial and vascular disease: vasculitis. BMJ 320:1325–1328PubMedCrossRef
3.
Ronda N et al (2007) In: Shoenfeld Y, Gershwin ME, Meroni PL (eds) Autoantibodies 2nd edn.. Elsevier Science BV,, Amsterdam, pp 725–731CrossRef
4.
Meroni P, Ronda N, Raschi E, Borghi MO (2005) Humoral autoimmunity against endothelium: theory or reality? Trends Immunol 26:275–281PubMedCrossRef
5.
Dieude M, Senecal JL, Raymond Y (2004) Induction of endothelial cell apoptosis by HSP 60-reactive antibodies from anti-endothelial cell autoantibody-positive SLE patients. Arthritis Rheum 50:3221–3231PubMedCrossRef
6.
Jamin C, Dugue C, Alard JE, Jousse S, Saraux A, Guillevin L, Piette JC, Youinou P (2005) Induction of endothelial cell apoptosis by the binding of anti-endothelial cell antibodies to HSP60 in vasculitis-associated systemic autoimmune diseases. Arthritis Rheum 52:4028–4038PubMedCrossRef
7.
Mandal K, Jahangiri M, Xu Q (2004) Autoimmunity to HSP in atherosclerosis. Autoimmun. Autoimmun Rev 3:31–37PubMedCrossRef
8.
Amberger A, Maczek C, Jurgens G, Michaelis D, Schett G, Trieb K, Eberl T, Jindal S, Xu Q, Wick G (1997) Co-expression of ICAM-1, VCAM-1, ELAM-1 and HSP60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones 2:94–103PubMedCrossRef
9.
Hochleitner BW, Hochleitner EO, Obrist P, Eberl T, Amberger A, Xu Q, Margreiter R, Wick G (2000) Fluid shear stress induces HSP 60 expression in endothelial cells in vitro and in vivo. Arterioscler Thromb Vasc Biol 20:617–623PubMed
10.
Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK (2000) Necrotic but not apoptotic cell death releases HSPs, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12:1539–1546PubMedCrossRef
11.
Saito K, Dai Y, Ohtsuka K (2005) Enhanced expression of HSPs in gradually dying cells and their release from necrotically dead cells. Exp Cell Res 310:229–236PubMedCrossRef
12.
Davies EL, Bacelar MM, Marshall MJ, Johnson E, Wardle TD, Andrew SM, Williams JH (2006) HSP form part of a danger signal cascade in response to lipopolysaccharide and GroEL. Clin Exp Immunol 145:183–189PubMedCrossRef
13.
Soltys BJ, Gupta RS (1999) Mitochondrial-matrix proteins at unexpected locations: are they exported? Trends Biochem Sci 24:174–177PubMedCrossRef
14.
Shaker O, Ay El–Deen MA, El Hadidi H, Grace BD, El Sherif H, Abdel Halim A (2007) The role of HSP 60, vascular endothelial growth factor and antiphospholipid antibodies in Behcet disease. Br J Dermatol 156:32–37PubMedCrossRef
15.
Nagafuchi H, Takeno M, Yoshikawa H, Kurokawa MS, Nara K, Takada E, Masuda C, Mizoguchi M, Suzuki N (2005) Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Behcet’s disease. Clin Exp Immunol 139:363–370PubMedCrossRef
16.
Imamura Y, Kurokawa MS, Yoshikawa H, Nara K, Takada E, Masuda C, Tsukikawa S, Ozaki S, Matsuda T, Suzuki N (2005) Involvement of Th1 cells and HSP 60 in the pathogenesis of intestinal Behcet’s disease. Clin Exp Immunol 139:371–378PubMedCrossRef
17.
Direskeneli H, Eksioglu-Demiralp E, Yavuz S, Ergun T, Shinnick T, Lehner T, Akoglu T (2000) T cell responses to 60/65 kDa HSP-derived peptides in Turkish patients with Behce’s disease. J Rheumatol 27:708–713PubMed
18.
Stanford M, Whittall T, Bergmeier LA, Lindblad M, Lundin S, Shinnick T, Mizushima Y, Holmgren J, Lehner T (2004) Oral tolerization with peptide 336–351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet’s disease. Clin Exp Immunol 137:201–208PubMedCrossRef
19.
Lehner T, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T (1991) Association between the 65-kDa HSP, Streptococcus sanguis, and the corresponding antibodies in Behcet’s syndrome. Infect Immun 59:1434–1441PubMed
20.
Tanaka T, Yamakawa N, Koike N, Suzuki J, Mizuno F, Usui M (1999) Behcet’s disease and antibody titers to various HSP 60s. Ocul Immunol Inflamm 7:69–74PubMedCrossRef
21.
Tripathy NK, Chauhan SK, Nityanand S (2004) Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu’s arteritis. Clin Exp Immunol 138:369–374PubMedCrossRef
22.
Chauhan SK, Tripathy NK, Nityanand S (2006) Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Takayasu arteritis. Arthritis Rheum 54:2326–2333PubMedCrossRef
23.
Lu W, Cheng P, Chen S (1998) HSP60, HSP70 in the pathogenesis of Kawasaki disease: implication and action. J Tongji Med Univ 18:145–148PubMedCrossRef
24.
Yin Ji X, Kang MR, Choi JS, Jeon HS, Han HS, Kim JY, Son BR, Lee YM, Hahn YS (2007) Levels of intra- and extracellular HSP 60 in Kawasaki disease patients treated with intravenous immunoglobulin. Clin Immunol 124:304–310PubMedCrossRef
25.
Strigl S, Kutlin A, Roblin PM, Shulman S, Hammerschlag MR (2000) Is there an association between Kawasaki disease and Chlamydia pneumoniae? J Infect Dis 181:2103–2105PubMedCrossRef
26.
Yokota S, Tsubaki K, Kuriyama T, Shimizu H, Ibe M, Mitsuda T, Aihara Y, Kosuge K, Nomaguchi H (1993) Presence in Kawasaki disease of antibodies to mycobacterial HSP65 and autoantibodies to epitopes of human HSP65 cognate antigen. Clin Immunol Immunopathol 67:163–170PubMedCrossRef
27.
Slot MC, Theunissen R, van Paassen P, Damoiseaux JG, Cohen Tervaert JW (2006) Evaluation of antibodies against human HSP60 in patients with MPO-ANCA associated glomerulonephritis: a cohort study. J Autoimmun Dis 5:3–4
28.
Winfield JB, Jarjour WN (1991) Stress proteins, autoimmunity, and autoimmune disease. Curr Top Microbiol Immunol 167:161–189PubMed
29.
Feige U, van Eden W (1996) Infection, autoimmunity and autoimmune disease. EXS 77:359–373PubMed
30.
Horvath L, Czirjak L, Fekete B, Jakab L, Prohaszka Z, Cervenak L, Romics L, Singh M, Daha MR, Fust G (2001) Levels of antibodies against C1q and 60 kDa family of HSP in the sera of patients with various autoimmune diseases. Immunol Lett 75:103–109PubMedCrossRef
31.
Yokota SI, Hirata D, Minota S, Higashiyama T, Kurimoto M, Yanagi H, Yura T, Kubota H (2000) Autoantibodies against chaperonin CCT in human sera with rheumatic autoimmune diseases: comparison with antibodies against other HSP60 family proteins. Cell Stress Chaperones 5:337–346PubMedCrossRef
32.
Shovman O, Sherer Y, Gilbourd B, Gerli R, Bocci EB, delle Monache F, Luccioli F, Shoenfeld Y (2005) Low levels of heat shock proteins-60 and -65 autoantibodies in Sjogren’s syndrome. Isr Med Assoc J 7:778–780PubMed
33.
Jarjour WN, Jeffries BD, Davis JS, 4th Welch WJ, Mimura T, Winfield JB (1991) Autoantibodies to human stress proteins. A survey of various rheumatic and other inflammatory diseases. Arthritis Rheum 34:1133–1138PubMedCrossRef
34.
Handley HH, Yu J, Yu DT, Singh B, Gupta RS, Vaughan JH (1996) Autoantibodies to human HSP 60 may be induced by Escherichia coli groEL. Clin Exp Immunol 103:429–435PubMedCrossRef
35.
Rudolphi U, Rzepka R, Batsford S, Kaufmann SH, von der Mark K, Peter HH, Melchers I (1997) The B cell repertoire of patients with rheumatoid arthritis. II. Increased frequencies of IgG+ and IgA+ B cells specific for mycobacterial HSP 60 or human type II collagen in synovial fluid and tissue. Arthritis Rheum 40:1409–1419PubMedCrossRef
36.
Multhoff G, Botzler C, Issels R (1998) The role of HSP in the stimulation of an immune response. Biol Chem 379:295–300PubMed
37.
Wick G, Knoflach M, Xu Q (2004) Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 22:361–403PubMedCrossRef
38.
Xu Q, Schett G, Perschinka H, Mayr M, Egger G, Oberhollenzer F, Willeit J, Kiechl S, Wick G (2000) Serum soluble HSP 60 is elevated in subjects with atherosclerosis in a general population. Circulation 102:14–20PubMed
39.
Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegard J (2000) Circulating HSP 60 is associated with early cardiovascular disease. Hypertension 36:303–307PubMed
40.
Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME (2004) Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 3:423–453PubMedCrossRef
41.
Pockley AG, Bulmer J, Hanks BM, Wright BH (1999) Identification of human HSP60 and anti-HSP60 antibodies in the peripheral circulation of normal individuals. Cell Stress Chaperones 4:29–35PubMedCrossRef
42.
Ronda N, Haury M, Nobrega A, Kaveri SV, Coutinho A, Kazatchkine MD (1994) Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients with SLE. Int Immunol 6:1651–1660PubMedCrossRef
43.
Zugel U, Kaufmann SH (1999) Role of HSPs in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 12:19–39PubMed
44.
Schett G, Xu Q, Amberger A, Van der Zee R, Recheis H, Willeit J, Wick G (1995) Autoantibodies against HSP 60 mediate endothelial cytotoxicity. J Clin Invest 96:2569–2577PubMedCrossRef
45.
Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, Shoenfeld Y, Youinou P (1998) The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 101:2029–2035PubMedCrossRef
46.
Uray K, Hudecz F, Fust G, Prohaszka Z (2003) Comparative analysis of linear antibody epitopes on human and mycobacterial 60- kDa HSPs using samples of healthy blood donors. Int Immunol 15:1229–1236PubMedCrossRef
47.
Perschinka H, Mayr M, Millonig G, Mayerl C, van der Zee R, Morrison SG, Morrison RP, Xu Q, Wick G (2003) Cross-reactive B-cell epitopes of microbial and human HSP 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol 23:1060–1065PubMedCrossRef
48.
Praprotnik S, Blank M, Meroni PL, Rozman B, Eldor A, Shoenfeld Y (2001) Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. Arthritis Rheum 44:1484–1494PubMedCrossRef
49.
Eichhorn J, Sima D, Thiele B, Lindschau C, Turowski A, Schmidt H, Schneider W, Haller H, Luft FC (1996) Anti-endothelial cell antibodies in Takayasu arteritis. Circulation 94:2396–2401PubMed
50.
Meroni PL, Youinou P (1996) In: Peter JB, Shoenfeld Y (eds) Autoantibodies.. Elsevier Science BV,, Amsterderm, pp 245–252CrossRef
51.
Yang YH, Wang SJ, Chuang YH, Lin YT, Chiang BL (2002) The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch-Schonlein purpura. Clin Exp Immunol 130:352–357PubMedCrossRef
Metadaten
Titel
HSP60 and Anti-HSP60 Antibodies in Vasculitis: They are Two of a Kind
verfasst von
Jean-Eric Alard
Maryvonne Dueymes
Pierre Youinou
Christophe Jamin
Publikationsdatum
01.10.2008
Verlag
Humana Press Inc
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 1-2/2008
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-007-8062-x

Weitere Artikel der Ausgabe 1-2/2008

Clinical Reviews in Allergy & Immunology 1-2/2008 Zur Ausgabe

OriginalPaper

The Unique Features of Vasculitis in Behçet’s Syndrome

OriginalPaper

Renal Involvement in Wegener’s Granulomatosis

OriginalPaper

The Last Classification of Vasculitis

OriginalPaper

Targeted Biologic Approaches to the Treatment of Systemic Vasculitis

OriginalPaper

The Geo-epidemiology of Temporal (Giant Cell) Arteritis

OriginalPaper

Wegener’s Granulomatosis: The Current View

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise